Gilead shares are trading lower after the company's Phase 3 TROPiCS-04 study missed its primary endpoint of overall survival.
Gilead Sciences, Inc. +2.17% Pre
Gilead Sciences, Inc. GILD | 88.16 88.16 | +2.17% 0.00% Pre |
Gilead shares are trading lower after the company's Phase 3 TROPiCS-04 study missed its primary endpoint of overall survival.